Lung adenocarcinoma can be classified according to the presence of major driver mutations in EGFR, KRAS, ALK, and BRAF, which confer clinical benefits to the subset of patients harboring them [4,5,6]. This evidence concerns the gene EGFR and lung adenocarcinoma.